Callum Health and Employer Health Innovation Roundtable (EHIR) A survey released found that employers’ desire to reduce healthcare spending and improve quality could lead to increased use of centers of excellence (COEs).
According to one study, overtreatment — including invasive procedures and unnecessary surgery — wastes up to $101 billion a year in the United States. study Published in the Journal of the American Medical Association.Also, surge in surgeries is expected due to pent-up demand 5% reduction from pre-pandemic levels by 2023, according to McKinsey. The combination of these factors led EHIR and Carrum Health to assess how employers view their overall surgical spending and its relationship to COE. Responses show that surgeries make up 34% of employers’ total spending, but most cost-reduction solutions many rely on don’t cover them.
“As COVID-19 exacerbates rising healthcare costs, this has become an even greater concern for self-financing employers. The pent-up demand for elective surgeries could have a significant impact on their total healthcare spending,” EHIR CEO Michael Michael Laquere said. “We’ve heard from EHIR members that they are concerned about rising surgery costs, and our survey, as well as anecdotal evidence, shows that our members are increasingly interested in a center of excellence because it can help reduce spending and improve quality.”
Carrum Health and EHIR conducted a survey of 217 benefit leaders working at U.S. companies with 3,000 or more employees that offer employee health insurance and self-insure.
Equivalent, An innovator in patient engagement and health relationship management solutions, good to know American College of Physicians(ACP), American Telemedicine Association (ATA) and ORCHA, the Nursing and Health Application Review Organization. In May, the groups announced a new framework for evaluating digital health technologies in the U.S., focused on helping physicians recommend high-value digital health tools to patients and identifying barriers to wider adoption of digital health tools.
“Leveraging the clinical expertise of ACP members, the technical expertise of ATA members, and ORCHA’s experience in evaluating applications to create a library of high-quality applications, this pilot project has the potential to meet the needs of many stakeholders,” said Ryan D. Mire , MD, FACP and ACP Chair recent press releases.
“We’ve seen the hyper-rapid development of digital health technologies over the years and the hyper-accelerated adoption of these solutions during the pandemic,” said Beth Strohbusch, Equiva’s head of marketing. “Our clients tell us that when evaluating digital patient engagement and education, How challenging is it to sort through the multitude of options when it comes to tools, not to mention the difficulty of managing the growing number of point solutions from multiple vendors.”
A digital health assessment framework is being developed to help healthcare organisations be confident that their recommended health and wellness tools meet quality, privacy and clinical assurance standards. “This is a positive step for patients, clinicians, healthcare organizations and digital health providers,” Strohbusch added.
Spectrum AnalyzerA digital health company focused on the autism spectrum has raised $9 million in a funding round co-led by F-Prime Capital and Frist Cressey Ventures. Other sources of investment include the Autism Impact Fund.
SpectrumAi’s technology is designed to improve the quality of applied behavioral analysis therapy for people with autism.
understand more, Click here.
transitional organism, a drug discovery platform company that uses biophysical science and artificial intelligence tools to map and modulate biomolecular condensates, raised $50 million in Series A funding led by Northpond Ventures. Taiho Ventures, Bristol Myers Squibb and Magnetic Ventures also participated in the round. Lifeforce Capital, the company’s lead investor in the seed round, also participated, joined by other existing seed investors.
In addition to fundraising, Dr. Shilpi Arora joined Transition Bio as Senior Vice President of Discovery Research and was previously Vice President of Discovery and Translational Biology at Exo Therapeutics.
To read more information, Click here.
SamaCareA pre-authorization platform for physician-administered medications, has closed a $12 million Series A round led by Clearlake Capital-backed Vive Collective. Other existing investors also participated in the round, including NextView Ventures, South Park Commons and Susa Capital. As part of the investment, Vive founder and CEO Cheryl Cheng will join the company’s board of directors.
The funding will help the company grow its physician practice clients, help it expand into existing and new specialties, increase client acquisition and support for pharmaceutical manufacturers, and add new executives.
To read more information, Click here.
picture: Arkindo, Getty Images
